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A B S T R A C T
Cystatin C (CysC) is a marker for estimation of glomerular ﬁltration rate (GFR). CysC levels may depend not only
on clearance/GFR but possibly also on changes in production. Our studies on tissue distribution of CysC protein
in mice showed that adipose tissue expresses signiﬁcant amounts of CysC, suggesting that adipocytes could
contribute to circulating CysC levels in vivo. As growth hormone (GH) and triiodothyronine (T3) increase both
GFR and CysC (increased in acromegaly and hyperthyroidism) in vivo, we studied whether they could increase
CysC production in 3T3-L1 adipocytes in vitro. CysC accumulated in culture media of 3T3-L1 adipocytes in a
time-dependent fashion. GH and T3 both (10 nmol/l) increased accumulation of CysC, to 373 ± 14 and
422 ± 20, respectively, vs 298 ± 10 ng per well over 4 days in controls. Thus, GH and T3 enhance the pro-
duction of CysC by adipocytes in vitro.
1. Introduction
Cystatin C (CysC) is a basic protein of 13’300 Da and a competitive
endogenous inhibitor of papain and related lysosomal cysteine protei-
nases. CysC is an excellent indicator of glomerular ﬁltration rate (GFR)
as it is released by most cells at a constant rate (Abrahamson et al.,
1990; Cole et al., 1989) and cleared from the bloodstream by the kid-
neys; it is ﬁltered by glomeruli and subsequently catabolized by tubular
epithelial cells. CysC concentration is negatively correlated with GFR
(Simonsen et al., 1985) and it is used as an alternative marker to
creatinine for estimation of GFR. However, plasma concentrations of
endogenous ﬁltration markers can be inﬂuenced by factors other than
GFR (non-GFR determinants), such as changes in production rate, renal
tubular reabsorption/secretion and extrarenal elimination. CysC is
considered superior to creatinine (predominantly produced in muscle)
as a marker for detection of mild renal dysfunction (in the “creatinine-
blind” range); moreover, CysC is an interesting biomarker associated
with aging, cardiovascular risk, frailty, and overall mortality (Astor
et al., 2012; Ballew et al., 2017; Emberson et al., 2010; Hart et al.,
2017; Ix et al., 2007; Koenig et al., 2005; Newman et al., 2016; Sarnak
et al., 2008; Shlipak et al., 2005; Tangri et al., 2012; Woitas et al., 2013;
Yamashita et al., 2013), particularly in elderly and in obese patients.
The latter may be due not just to diﬀerences in renal handling of
creatinine and CysC, but also due to diﬀerences in tissue origin and
production rates of the two compounds. Whereas the muscular origin of
creatinine is well documented, the relative contribution of several or-
gans to circulating levels of CysC is unknown and diﬃcult to estimate.
Adipose tissue may contribute signiﬁcantly to elevated serum CysC
(Naour et al., 2009). CysC has been found to increase with obesity
(Naour et al., 2009; Chew-Harris et al., 2013; de Boer et al., 2012;
Muntner et al., 2008; Shankar and Teppala, 2011; Young et al., 2008;
Stevens et al., 2009), to rise in proportion to the number of metabolic
syndrome components, and to be associated with insulin resistance and
endothelial dysfunction (Lee et al., 2010; Murai et al., 2017; Servais
et al., 2008; Surendar et al., 2010; Vigil et al., 2009). Increased serum
levels of CysC have been found indicative of the metabolic syndrome
and type 2 diabetes (Donahue et al., 2007; Magnusson et al., 2013;
Reutens et al., 2013; Sahakyan et al., 2011). Interestingly, this re-
lationship between levels of serum CysC and insulin resistance was
found not only in type 2 but also in type 1 diabetes (Uruska et al.,
2014). Although CysC can be considered as a marker and predictor of
insulin resistance (de Boer et al., 2012; Lee et al., 2010; Servais et al.,
2008; Surendar et al., 2010; Vigil et al., 2009; Codoner-Franch et al.,
2011; Lee et al., 2009), it remains unclear whether and to what extent
this epidemiological association is based on altered adipose tissue mass
and/or function (Naour et al., 2009; Naour et al., 2010), e.g. in the
context of inﬂammation of adipose tissue or of hyperinsulinemia. CysC
appears to play an important role in adipose tissue remodelling. It
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inhibits the protease activity of cathepsin S, a biomarker for adiposity
that is expressed by adipose tissue and up-regulated in obesity. Cathe-
psin S degrades several extracellular matrix (ECM) proteins, including
ﬁbronectin. ECM proteins are downregulated and CysC expression is
upregulated during the process of adipocyte diﬀerentiation
(Kratchmarova et al., 2002; Taleb et al., 2005).
Tissue-speciﬁc expression of CysC has been studied in mice. Huh
et al. found that CysC mRNA expression was especially high in brain
and testis, and low in liver and pancreas (Huh et al., 1995). Hakansson
(Hakansson et al., 1996) and Jiborn (Jiborn et al., 2004) measured
CysC by immunoassay in various mouse tissues and found high abun-
dance in brain and low abundance in liver; the abundance was inter-
mediate in skeletal muscle. These authors did not comment on adipose
tissue although this tissue may be a relevant source contributing to
circulating CysC.
Non-GFR determinants of CysC have been inferred mainly from
cross sectional studies and remain poorly deﬁned (Levey et al., 2014).
Besides abdominal obesity and insulin, there are speciﬁc endocrine
disorders that may aﬀect CysC levels independently of GFR. Hy-
pothyroidism and hypopituitarism are associated with lower CysC
serum levels that increase upon thyroid hormone replacement therapy
(Fricker et al., 2003; Goede et al., 2009). Remarkably, growth hormone
(GH) or thyroid hormone excess (acromegaly and hyperthyroidism)
both lead to concomitant increases in GFR and CysC levels, which can
be reversed following successful treatment (Fricker et al., 2003; Sze
et al., 2013). Thyroid dysfunction and acromegaly lead to discrepancies
in CysC and creatinine levels (Fricker et al., 2003; Goede et al., 2009;
Sze et al., 2013; den Hollander et al., 2003; Jayagopal et al., 2003;
Kotajima et al., 2010; Manetti et al., 2005; Wiesli et al., 2003). Thyroid
hormones and GH may increase the production of CysC so that its levels
could increase despite an increased clearance of creatinine and an
elevated GFR.
3T3-L1 cells (Green and Meuth, 1974) have been used to study
diﬀerentiation of adipocytes in vitro. Diﬀerentiation of these cells to
adipocytes can be monitored by assessing preadipocyte factor-1 (Pref-
1). Pref-1 was cloned from 3T3-L1 cells (Smas and Sul, 1993) and is
highly expressed in proliferating adipocyte-lineage committed ﬁbro-
blasts/preadipocytes but absent in diﬀerentiated adipocytes. Proteomic
approaches for identiﬁcation of proteins expressed and secreted by
adipocytes have found CysC as a prominent protein that is upregulated
with diﬀerentiation, and increasingly secreted in response to insulin
(Kratchmarova et al., 2002; Molina et al., 2009; Zhou et al., 2009).
Furthermore, it has been found that T3 stimulates glucose uptake in
3T3-L1 adipocytes in long term culture, as also in a rat liver cell line, in
cardiomyocytes, and in preosteoblasts (Gosteli-Peter et al., 1996; Lin
and Sun, 2011; Romero et al., 2000; Weinstein et al., 1990; Zoidis et al.,
2012). Classical insulin target tissues such as liver, striated muscle, and
adipose tissue may be particularly responsive to GH. Indeed, 3T3-L1
ﬁbroblasts and adipocytes have been used to test eﬀects of GH on dif-
ferentiation and glucose uptake, respectively (Frost and Lane, 1985;
Green et al., 1985; Stewart et al., 2004), and to study insulin-antag-
onistic eﬀects of GH (Sasaki-Suzuki et al., 2009; Takano et al., 2001).
By activating the JAK-STAT pathway, GH plays an important role in
regulating adipogenesis and adipose tissue function (Richard and
Stephens, 2014).
We studied tissue distribution of CysC in mice, including adipose
tissue. We could conﬁrm previous results showing high expression in
pituitary and brain, and low expression in liver. In addition, we found
signiﬁcant expression of CysC in adipose tissue depots. The main goal of
our study was to test if GH and T3 directly regulate CysC production in
adipocytes. Since it is diﬃcult to exclude indirect eﬀects in vivo, we
decided to perform experiments in vitro. We chose the 3T3-L1 pre-
adipocyte/adipocyte model, an adipocytic cell line that is well char-
acterized, and is responsive to both of these hormones. We conﬁrmed
that GH and insulin stimulate phosphorylation of Stat5 and Akt/PKB in
3T3-L1 cells after several days of serum deprivation. We then studied
whether GH and T3 regulate the production of CysC, and we compared
their eﬀects with those of dexamethasone.
2. Materials and methods
2.1. Materials
Cell culture media, fetal calf serum (FCS), penicillin/streptomycin,
glutamine, and trypsin were purchased from Thermo Fisher
(Switzerland). Fatty acid-free bovine serum albumin (BSA) was from
Sigma (Darmstadt, Germany). Dexamethasone (dex) was from Sigma
and dissolved as a stock solution of 1mmol/l in absolute ethanol.
Triiodothyronine (T3, 3,3′,5-triiodo-l-thyronine, sodium salt) was pur-
chased from Sigma (St. Louis MO, USA), and, prior to use, dissolved as a
stock solution of 1mmol/l in 10mmol/l NaOH. Isomethylbutylxanthine
(IBMX) was from Sigma, GH and human insulin were kindly provided
by Novo Nordisk (Gentofte, Denmark). 2-deoxy-D-[1–14C] glucose
(0.2 μCi/ml; 58mCi/mmol) was from Perkin Elmer (Waltham MA,
USA).
2.2. Isolation of tissues from mice
Wild type mice (C57BL/6) on standard chow diet (Provimi Kliba SA,
Kaiseraugst, Switzerland) were housed in groups of up to ﬁve litter-
mates with 12 h dark-light cycle at 21 °C and were allowed free access
to food and water. Breeding of mice and all conducted procedures were
carried out in agreement with Swiss animal protection laws and were
approved by the appropriate authorities. 52 days-old mice were sacri-
ﬁced and their organs dissected. Tissues were homogenized in
50mmol/l HEPES pH 7.5, 140mmol/l NaCl, 1 mmol/l PMSF, 0.5%
Triton X-100, 10mmol/l NaF, 1mmol/l Na2H2P2O7, 1mmol/l Na2O4V,
3 μg/ml aprotinin, 3 μg/ml leupeptin. Protein concentration in cleared
lysates was determined by the bicinchoninic acid (BCA) protein assay
kit from Pierce (USA, Rockford IL). As protein yield was low from
adipose tissue and endocrine organs, tissues were pooled from four
animals. Homogenates were stored at −70 °C until used.
2.3. Cell culture
3T3-L1 cells (a mouse preadipocytic cell line, purchased from ATCC,
Manassas, USA) were cultured and passaged in TPP tissue culture ﬂasks
(Trasadingen, Switzerland) in Dulbecco's modiﬁed Eagle's medium
(DMEM) containing 25mmol/l glucose. 10% (v/v) FCS, 1% penicillin,
1% streptomycin, and 2mmol/l L-glutamine. The cells were kept at
37 °C in an atmosphere of 5% v/v CO2 in air.
As shown in Fig. 1, cells were plated and cultured under conditions
initiating diﬀerentiation of 3T3-L1 ﬁbroblasts into adipocytes. Cells
were seeded (12’500 cells/cm2) on gelatinized plates and cultured in
growth medium for 3 days with high D-glucose DMEM containing FCS
(10%), L-glutamine, and penicillin/streptomycin as described above.
For the next two days (3–5) the DMEM contained 2% FCS, L-glutamine,
penicillin/streptomycin and diﬀerentiation mix (1.7 μmol/l insulin,
1 μmol/l dex, 0.5mmol/l IBMX and 1 μmol/l rosiglitazone). Cells were
washed with PBS and kept in serum-free DMEM, containing 1 g/l BSA,
glutamine, penicillin/streptomycin, 100 nmol/l dex, and 10 nmol/l in-
sulin for two days (5–7). Cells were washed with PBS prior to culture in
serum-free DMEM, containing 1 g/l BSA, glutamine, penicillin/strep-
tomycin for the last four days (7–11). Hormones or corresponding ve-
hicles were directly added to the media, unless indicated otherwise.
Supernatants were collected and cells were lysed after 11 days of cul-
ture.
2.4. Assessment of 2-deoxyglucose uptake (glucose transport)
Cells were grown in multiwell tissue culture dishes (35mm dia-
meter). Insulin-dependent uptake of 2-deoxy-D-[1–14C] glucose (2DG)
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was allowed over 10min at room temperature as described previously
(Zoidis et al., 2012). In brief, monolayers were washed at room tem-
perature with 1ml transport buﬀer containing 140mmol/l NaCl,
5 mmol/l KCl, 1 mmol/l MgCl2, 1.5 mmol/l CaCl2, and 15mmol/l N-2-
hydroxyethylpiperazine- N-2-ethanesulfonic acid (HEPES, adjusted to
pH 7.4 with Tris-HCl). Uptake studies were initiated by adding 1ml of
transport buﬀer containing 0.1 mmol/l cold 2DG and [1–14C]2DG
(0.2 μCi/ml). Ten minutes later, the buﬀer was removed and the dishes
were quickly rinsed three times with 1ml of ice-cold transport buﬀer.
The cells were then solubilized with 1ml of 2% w/v sodium dodecyl
sulfate (SDS), and the radioactivity of a 0.5 ml aliquot was measured in
a liquid scintillation counter.
Protein content was determined in parallel in identically treated
dishes. After 11 days of culture (of which six days in serum-free
medium and the last four days in test medium), cells from parallel
dishes were lysed into 1ml of 0.1% w/v Triton X-100 for the de-
termination of protein content by a modiﬁcation of the Lowry proce-
dure or by the bicinchoninic acid (BCA) method (Pierce, Rockford IL,
USA) as described (Zoidis et al., 2012).
2.5. RNA extraction and quantitative RT-PCR
Total RNA was extracted from 3T3-L1 ﬁbroblasts or adipocytes
(grown on 12-well plates, 50’000 cells seeded per 3.5 cm2) using the
NucleoSpin® RNA Kit (Macherey-Nagel). Concentration and purity of
the extracts were analysed with a NanoDrop Lite spectrophotometer
(Thermo Scientiﬁc). RNA (0.30 μg) was reverse transcribed with
Superscript III Reverse Transcriptase (Thermo Fisher) using random
hexamer primers (Thermo Fisher). A 7500 FAST Real-Time PCR system
(Applied Biosystems) was used for real-time PCR ampliﬁcation.
Relative gene expression was obtained after normalization to 18s RNA,
using formula 2–ΔΔcp. The following primers (Applied Biosystems) were
used: Mm00438347_m1 for cysC mRNA and Mm03928990_g1 for 18s
ribosomal RNA.
2.6. Immunoblotting
Cells were rinsed and lysed in 50mmol/l HEPES pH 7.5, 140mmol/
l NaCl, 1 mmol/l PMSF, 0.5% Triton X-100, 10mmol/l NaF, 1mmol/l
Na2H2P2O7, 1mmol/l Na2O4V, 3 μg/ml aprotinin, 3 μg/ml leupeptin.
Protein concentration in cleared lysates was determined by the bi-
cinchoninic acid (BCA) protein assay kit from Pierce (USA, Rockford
IL). Equal amounts of protein (tissue homogenate or cell lysate) were
separated by SDS-PAGE (NuPAGE, Thermo Fisher, Switzerland) and
transferred onto nitrocellulose membranes. 2% non-fat milk in TBST
(10mmol/l Tris-HCL, pH 7.4, 150mmol/l NaCl, 0.05% (v/v) Tween
20) was used to block nonspeciﬁc binding of antibodies to membranes.
Incubation with primary and secondary antibodies was either at room
temperature for 1 h or overnight at 4 °C. Equal loading and transfer was
conﬁrmed by Ponceau S staining and with an antibody against actin
Fig. 1. Flow diagram (time course) of cell treatment protocols.
Cells were cultured for 3 or 11 days. In the latter case, the last 6 days were without serum. GH, T3, dex, or insulin were added as indicated. Cells were characterized
and Insulin responsiveness was assessed as shown in A. Fibroblasts/preadipocytes after 3 days and adipocytes after 11 days. For long-term incubations with GH or T3,
two distinct protocols were used (A and B). Protocol B includes media replacement at diﬀerent time points to assess time-dependent hormone eﬀects and accu-
mulation of CysC in culture media as shown in Fig. 4.
C. Schmid et al. Molecular and Cellular Endocrinology 482 (2019) 28–36
30
(MAB1501: EMD Millipore, Temecula, USA). GH- and insulin-depen-
dent signaling was assessed with antibodies against the phosphorylated
forms of Stat5a/b (Tyr 694): Santa Cruz, Dallas, USA and Akt/PKB
(Ser473): Cell Signaling, Danvers, USA and ERK1/2 (Thr202/Tyr204):
Cell Signaling, Danvers, USA. For analysis of CysC, cystatin C (rabbit
polyclonal) antiserum was from DAKO (Glostrup, Denmark), the sec-
ondary antibody, goat anti-rabbit HRP, from Bio-Rad (Reinach,
Switzerland); both were used at a dilution of 1:3000. Pref-1/DLK1/FA1
antibody (goat polyclonal) was from R&D Systems (Minneapolis, USA)
and used at a dilution of 1:1000; the secondary antibody (donkey anti-
goat) was from Santa Cruz (Dallas, USA). PPARɣ antibody was from
Santa Cruz (Dallas, USA) and used at a dilution of 1:1000. Immuno-
reactive proteins were visualized by the Lumi-Light Western Blotting
Substrate (Roche) using a LAS-3000 imaging system (Fuji). Signal in-
tensities were quantiﬁed using the AIDA software package from Raytest
(Germany).
2.7. ELISA for cystatin C
Cell culture media were collected as described above and analysed
by a sandwich enzyme immunoassay for quantitative measurement of
mouse CysC (BioVendor, Modrice, Czech Republic). The polyclonal
antibodies have been raised against mouse CysC that was also used for
the calibration curve. Determination of CysC in mouse tissue extracts
was as described for cell culture media.
2.8. Statistical analysis
Results were obtained by pooling data from independent experi-
ments in which the same conditions were tested, as indicated. Data are
expressed as means ± S.E.M. Statistical signiﬁcance was checked by
Fig. 2. Tissue-speciﬁc expression of CysC in mice.
Tissue extracts from male mice were loaded onto SDS-PAGE and blotted to
nitrocellulose membranes. Proteins were stained by Ponceau S (A). Actin and
CysC were assessed with speciﬁc antibodies (B). To quantify CysC protein, the
same extracts were analysed by ELISA (C); results are shown as mean ± SEM.
The following tissues were analysed: Brain (br), skeletal muscle (mus), liver
(liv), epididymal adipose tissue (at-ep), perirenal adipose tissue (at-pr), testis
(tes), and adrenal (adr) and pituitary (pit) gland.
Table 1
CysC expression in 3T3-L1 ﬁbroblasts and adipocytes.
Cells were cultured for 3 days or 11 days as outlined in Fig. 1A. mRNA ex-
pression of CysC was assessed by quantitative RT-PCR and is presented nor-
malized for day 3 and to 18S RNA, 2–ΔΔcp (n=2 in duplicate). Abundance of
CysC protein in cell layers normalized to day 3 was assessed by densitometric
analysis of Western blots (n= 3 in duplicate).
cystatin C d3 (ﬁbroblasts) d11 (adipocytes)
mRNA (1) 2.37 ± 0.39
protein (1) 3.04 ± 0.38
Fig. 3. Hormone responsiveness of 3T3-L1 cells and expression of Pref-1,
PPARγ and CysC.
Western analysis of Pref-1, PPARγ and CysC (A) and p-Stat5a/b, p-Akt/PKB,
and p-ERK1/2 (B) in ﬁbroblasts/preadipocytes (3d of culture) and in adipocytes
(11 d in culture) exposed to 10 nMGH or 100 nM insulin for 30min. Actin was
visualized as a control. Cells were kept on dishes for 3 days or 11 days as
outlined in Fig. 1A, and exposed to medium containing hormones for the last
30min.
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paired Student's t-test or ANOVA, as appropriate. A P-value< 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Tissue distribution of CysC in mice
Tissue-speciﬁc expression of CysC in mice was assessed in organ
protein extracts by Western blotting and ELISA (Fig. 2).
Immunoblots revealed signiﬁcant diﬀerences in CysC expression
among tissues analysed and a representative blot is shown in Fig. 2A
and B. CysC was most abundant in the pituitary gland and lowest in
liver. Intermediate expression was observed in brain, muscle, adipose
tissue, testis and ovaries (not shown), and the adrenal gland.
Results obtained by ELISA correspond well with those from im-
munoblotting (Fig. 2C and B). We analysed males and females sepa-
rately, however, only minor diﬀerences were observed. Pituitary con-
tained the highest levels of CysC (> 100 ng/mg protein) and liver
extracts the lowest (1.8 ± 0.5 ng/mg protein). Signiﬁcantly higher
levels than in liver were found in brain (62 ± 11 ng/mg protein),
muscle (25 ± 5 ng/mg protein), adipose tissue depots (perigonadal,
perirenal, and subcutaneous, on average, 39 ± 7 ng/mg protein), testis
(38 ± 15 ng/mg protein), ovaries (17 ± 5 ng/mg protein), and
adrenal gland (52 ± 13 ng/mg protein). Serum concentration of CysC
(mean ± SD) was not diﬀerent in male (628 ± 136 ng/ml, n= 8) and
in female (586 ± 107 ng/ml, n= 8) animals.
3.2. Hormone responsiveness and expression of CysC in 3T3-L1 cells
High expression levels of CysC in adipose tissue from mice suggested
that adipocytes could indeed contribute to alterations in circulating
CysC levels in vivo.
First, expression of CysC was assessed at the RNA and protein levels
in 3T3-L1 cells after 3 and 11 days of culture. As shown in Table 1, more
Table 2
Eﬀects of GH, T3, and dex on 2DG uptake.
Cells were cultured for 11 days and exposed to GH [10 nM] or T3 [10 nM] (A)
or dex [100 nM] (B) for the last 4 days of culture; the medium was changed
after 92 h and insulin was included in the test medium for the last 4 h (protocol
as in Fig. 1A). 2DG uptake was measured over a period of 10 min. Values are
mean ± SEM from at least 5 experiments in triplicate; *p < 0.05 for com-
parison of GH or T3 vs control. ns for comparison of dex vs control.
A
2DG uptake (pmol/mg protein x 10min)
insulin [nM]
0 1 100
Control 232 ± 20 379 ± 37 836 ± 44
GH [10 nM] 221 ± 23 293 ± 3 641 ± 52*
T3 [10 nM] 364 ± 40* 576 ± 53* 1048 ± 59*
B
2DG uptake (pmol/mg protein x 10min)
insulin [nM]
0 1 100
Control 282 ± 33 479 ± 71 898 ± 117
dex [100 nM] 373 ± 22 549 ± 45 868 ± 56
Table 3
Eﬀects of GH, T3, and dex on CysC production.
Cells were exposed to GH [10 nM] or T3 [10 nM] (A) or dex [100 nM] (B) for the last 4 days of culture as shown in Fig. 1A and the 96 h time point of Fig. 4. Media
(supernatant) as well as cell layers (protein extracts) were analysed by both ELISA and immunoblotting. As shown here and also stressed in the legend to Fig. 4, much
more CysC protein accumulates over 4 days in the media (ELISA, n = 11; immunoblot, n = 6) than in the cell layers (ELISA, n = 4; immunoblot, n = 4). *p < 0.05
for comparison of hormone-treated vs control.
A
cystatin C
cell layer supernatant
ELISA ng/well x 4 d
(relative to control)
Immunoblot densitometry
(relative to control)
ELISA ng/well x 4 d
(relative to control)
Immunoblot densitometry
(relative to control)
control 17.1 ± 1.8
(1)
(1) 298 ± 10
(1)
(1)
GH [10 nM] 28.6 ± 8.3
(1.46 ± 0.28)
(1.10 ± 0.03) 373 ± 14*
(1.25 ± 0.03)*
(1.18 ± 0.09)
T3 [10 nM] 32.8 ± 5.7
(1.79 ± 0.16)*
(1.37 ± 0.05) 422 ± 20*
(1.41 ± 0.04)*
(1.22 ± 0.06)
B
cystatin C
cell layer supernatant
ELISA ng/well x 4 d
(relative to control)
Immunoblot densitometry
(relative to control)
ELISA ng/well x 4 d
(relative to control)
Immunoblot densitometry
(relative to control)
control 17.4 ± 1.6
(1)
(1) 241 ± 20
(1)
(1)
dex [100 nM] 22.0 ± 2.5
(1.23 ± 0.08)*
(1.34 ± 0.10) 283 ± 19
(1.22 ± 0.09)*
(1.17 ± 0.10)
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cysC mRNA and CysC protein was found in adipocytes than in ﬁbro-
blasts.
Diﬀerentiation of ﬁbroblasts (day 3) to adipocytes (day 11) was
conﬁrmed by assessment of actin, Pref-1 and PPARγ (1 and 2) expres-
sion. After diﬀerentiation of our cells from ﬁbroblasts into adipocytes,
actin expression was decreased, and Pref-1 was no longer detectable
(Fig. 3A). PPARγ 1 and 2 were upregulated, and the abundance of CysC
protein was higher in adipocytes than in ﬁbroblasts.
In order to further characterize our 3T3-L1 cells, we also assessed
responsiveness to insulin and GH by measuring activation of corre-
sponding signal transduction components and glucose uptake. As
shown in Fig. 3B, ﬁbroblasts and adipocytes were both responsive to
insulin and GH. As expected, GH increased p-Stat-5a/b and p-ERK1/2,
insulin increased p-Akt/PKB and p-ERK1/2. Basal and 1 nM and 100 nM
insulin-stimulated 2DG uptake were assessed in 3T3-L1 adipocytes. GH,
T3, and dex were included for the last 4 days of culture (according to
protocol in Fig. 1A). GH did not signiﬁcantly aﬀect basal but decreased
insulin-dependent 2DG uptake. T3 stimulated basal and insulin-depen-
dent 2DG uptake. Dex tended to increase basal 2DG uptake, but had no
signiﬁcant eﬀect (Table 2).
3.3. Eﬀects of GH, T3, and dex on CysC production in 3T3-L1 adipocytes
The production of CysC was studied in 3T3-L1 adipocytes by ELISA
and results are shown in Table 3. During 4 days of culture, more CysC
accumulated in supernatants (298 ± 10 ng/well) than in cell layers
(17.1 ± 1.8 ng/well). Inclusion of T3 [10 nM] during this period sig-
niﬁcantly increased CysC in cell layers (1.79 ± 0.16 fold) and in su-
pernatants (1.41 ± 0.04 fold). GH [10 nM] increased CysC in super-
natants (1.25 ± 0.03 fold). Additional assessment of CysC by
immunoblotting essentially conﬁrmed our results. Inclusion of dex
[100 nM] also increased the production of CysC (Table 3B),
1.23 ± 0.08 fold in cell layers and 1.22 ± 0.09 fold in supernatants.
Next, time-dependency of CysC production was studied. 3T3-L1
adipocytes (day 11, protocol according to Fig. 1B) were exposed to GH
[10 nM] or T3 [10 nM] for 4 d, 1 d, or 6 h prior to analysis. Both GH and
T3 increased accumulation of CysC in supernatants over time, as found
by ELISA (Fig. 4A) and immunoblotting (Fig. 4B). However, increases in
CysC due to exposure to GH and T3 were small and reached signiﬁcance
only after 4 d. Levels of CysC in supernatants after 4 days were far
higher than in cell layers: 20 times less of the conditioned supernatants
resulted in comparable signal intensities as seen with cell layer lysates
(Fig. 4B). These ﬁndings with Western blotting agree well with results
obtained by ELISA as presented in Table 3. In cell layers, similar levels
of CysC were found at 6 h, 1 d, and 4 d. No diﬀerence in migration of
CysC from cell layers or supernatants was found. As shown in Fig. 4C,
inclusion of GH resulted in marked phosphorylation of Stat5 both after
shorter and longer exposure times. GH did not aﬀect phosphorylation of
Akt/PKB or ERK1/2.
Regulation of CysC production by GH and T3 was dose-dependent
(Table 4A). Cells were cultured in the absence or presence of increasing
hormone concentrations for 4 d and CysC was determined in culture
media by ELISA. 10 nM of GH or at least 1 nM of T3 were required to
achieve a signiﬁcant stimulation of CysC of up to 1.4 fold. Furthermore,
GH and T3 when present in combination resulted in an additive increase
in CysC (Table 4B).
4. Discussion
Analysis of tissue distribution of CysC in mice conﬁrmed high ex-
pression in pituitary and brain, and low expression in liver. In addition,
adipose tissue depots showed signiﬁcant expression of CysC. We could
also conﬁrm that CysC expression is upregulated during the process of
adipocyte diﬀerentiation (Kratchmarova et al., 2002; Taleb et al.,
2005). In our in vitro system, upregulation of CysC was associated with
downregulation of the adipogenesis inhibitor pref-1 as well as an in-
creased abundance of diﬀerentiation markers PPARγ 1 and 2 (both
required for normal adipogenesis), in line with previous reports (Smas
and Sul, 1993; Takenaka et al., 2013).
Our results conﬁrm that 3T3-L1 preadipocytes/adipocytes express
CysC and release the protein into the media where it accumulates in a
time-dependent fashion. CysC production is regulated in vivo and in
vitro by external factors, such as cellular stress and various hormones
including insulin at high concentrations (Molina et al., 2009; Zhou
et al., 2009; Wang et al., 2006). In response to insulin exposure for 4
days (day 7–11), there was a signiﬁcant dose-dependent increase of
CysC in supernatants (not shown). It is noteworthy that more global,
unbiased approaches identiﬁed CysC as a protein whose secretion was
increased in response to supraphysiological doses of insulin, in rat and
mouse adipocytes (Zhou et al., 2009; Wang et al., 2006; Chen et al.,
2005).
Both T3 and GH stimulated 3T3-L1 adipocytes to increase the re-
lease of CysC into the culture medium. In serum-free cultures, CysC in
Fig. 4. Time-dependent eﬀects of GH and T3 on CysC, p-Stat5a/b, p-Akt/PKB,
p-ERK1/2 in 3T3-L1 adipocytes.
Cells were kept on dishes for 11 days and exposed to GH [10 nM] or T3 [10 nM]
for 4 d, 1 d, or 6 h prior to analysis as shown in Fig. 1B. A: Accumulation of CysC
over time in media assessed by ELISA, from 5 experiments carried out in tri-
plicate; *p < 0.05, **p < 0.001. B: Representative immunoblot with protein
extracts from cell layers (∼12% of the lysate, upper panel) and media (∼0.6%
of the supernatant, lower panel). C: Representative immunoblot with protein
extracts from cell layers showing phosphorylation of Stat5a/b, Akt/PKB, and
ERK1/2; actin as loading control.
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the medium reﬂects the net release of the protein by the cells. We found
a linear increase of CysC in the medium over time (Fig. 4) suggesting
that production and secretion by far exceed degradation (or uptake) of
the protein in this cell culture system. Culturing the cells under serum-
free conditions allowed us to test the eﬀects of T3, GH and insulin
without interference by other FCS-contained hormones. To avoid vari-
able residual serum eﬀects, the experiments addressing actions of GH
and T3 share a common culture period including the same time in
serum-free medium. Furthermore, protein content of cell layers was
determined in every experiment, and only wells with similar protein
content were used to exclude possible unspeciﬁc eﬀects.
Western analysis revealed CysC in cell layers and in supernatants at
day 3 and at day 11; in all cases, CysC appeared to have the same
molecular size (Figs. 3 and 4). According to our experience, quantiﬁ-
cation of CysC by ELISA was more precise than semiquantitative esti-
mation by Western blotting. Nevertheless, ﬁndings by ELISA and Wes-
tern analysis were in excellent agreement, and the latter corroborated
the identity of the assessed protein and the reliability of our data.
We have studied the regulation of the production of CysC but not its
role, which is mainly the local control of proteolysis. In the cells stu-
died, production greatly exceeded disappearance of CysC. In vivo, the
disappearance of CysC from the circulation predominantly depends on
renal glomerular ﬁltration and degradation by kidney tubular epithelial
cells although other cells may also internalize the protein. The relative
contribution of several organs to circulating levels of CysC is unknown
and diﬃcult to estimate. Adipose tissue may contribute signiﬁcantly to
elevated serum CysC as observed in human obesity and hyper-
insulinemia. Spillover of CysC into the blood stream is apparently in-
creased in hyperthyroidism and acromegaly, to an extent that serum
CysC no longer reﬂects GFR. T3 stimulates CysC production in two other
cell types: in Hep G2 cells (kept in thyroid hormone-stripped medium),
as assessed by RT-PCR of the cells and a nephelometric immunoassay of
the media, by about 30% (Kotajima et al., 2010), and in preosteoblasts
(kept in serum-free medium), as assessed by Northern analysis and
analysis of the protein in the media by Western and ELISA, by about
50% (Schmid et al., 2012).
We found that most of the CysC produced by 3T3-L1 adipocytes is
released into the media and not retained in the cell layer (Table 3, and
Fig. 4). It is striking that 3T3-L1 preadipocytes/adipocytes released
about 10 times more CysC than preosteoblasts. In those cells, we hardly
could detect CysC in the cell layers by Western analysis, and detection
of CysC in supernatants required concentrating the samples (Schmid
et al., 2012). Our observation that T3 stimulated CysC production in
3T3-L1 cells conﬁrms and extends previous ﬁndings with other cell
types. As adipocytes may be a major source of circulating CysC in vivo,
stimulation by T3 could explain increased serum CysC in hyperthyr-
oidism. Our ﬁndings of CysC stimulation by GH are original and need to
be conﬁrmed. Stimulatory eﬀects of GH and T3 on CysC in vivo are
diﬃcult to separate; GH can stimulate production and action of T3
(Goede et al., 2009; Sze et al., 2013; Hussain et al., 1996; Martins et al.,
2007). In our in vitro experiments, cells cultured in the presence of ei-
ther GH or T3 alone released more CysC compared to controls, and the
combination of the two appeared to have additive rather than sy-
nergistic eﬀects.
It has been reported that dex can stimulate CysC gene expression
and CysC protein production in tumour cells and more strongly in an
osteoblastic cell line (Schmid et al., 2012; Bjarnadottir et al., 1995;
Yamawaki et al., 2013). Dex was much less potent in 3T3-L1 cells
(Table 3B). In contrast to the eﬀects of GH and T3 (p < 0.001), those of
dex hardly reached signiﬁcance. This is in line with in vivo ﬁndings that
showed inconsistent and controversial inﬂuence of glucocorticoids on
serum CysC (Goede et al., 2009; Bokenkamp et al., 2002).
Thyroid hormones and GH increase cell metabolism; therefore, the
demand for proteolysis control may also increase. Similar to oxidative
stress and cellular damage, the increased cellular and metabolic turn-
over in hyperthyroidism and acromegaly is associated with accelerated
aging and increased mortality; higher serum levels of CysC in such
disease conditions may reﬂect this. More speciﬁcally, T3 stimulation of
CysC production by several cells and spillover into the circulation may
account for the dependency of CysC serum levels on GH and T3 in vivo.
Rather than being dominated by renal catabolism and clearance (as-
suming production rate to be constant), increased plasma CysC in hy-
perthyroidism and acromegaly (in the face of increased GFR) appear to
reﬂect an important impact of thyroid hormones and GH on the pro-
duction of CysC.
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